UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 185

Sortiert nach

Integrated safety in tocilizumab clinical trials

Arthritis research & therapy, 2011-01, Vol.13 (5), p.R141-R141

2011

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort

Seminars in arthritis and rheumatism, 2015-08, Vol.45 (1), p.28-34

2015

Link zum Volltext

Verfügbarkeit prüfen

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)

Journal of rheumatology, 2003-12, Vol.30 (12), p.2563

2003

Link zum Volltext

Verfügbarkeit prüfen

Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration

Annals of the rheumatic diseases, 2014-08, Vol.73 (8), p.1549-1551

2014

Link zum Volltext

Verfügbarkeit prüfen

Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience

Journal of rheumatology, 2006-05, Vol.33 (5), p.854

2006

Link zum Volltext

Verfügbarkeit prüfen

Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis

Rheumatology international, 2017-02, Vol.37 (2), p.213-218

2017

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis

Journal of rheumatology, 2004-06, Vol.31 (6), p.1098

2004

Link zum Volltext

Verfügbarkeit prüfen

Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase

Annals of the rheumatic diseases, 2014-12, Vol.73 (12), p.2174-2177

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study

Annals of the rheumatic diseases, 2018-05, Vol.77 (5), p.658

2018

Link zum Volltext

Verfügbarkeit prüfen

Future Refinement of Methotrexate Treatment in Rheumatoid Arthritis: Comment on the Article by Yazdany et al

Arthritis care & research (2010), 2013-11, Vol.65 (11), p.1892-1892

Schiff, Michael H.

2013

Link zum Volltext

Verfügbarkeit prüfen

Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability

Journal of rheumatology, 2004-08, Vol.31 (8), p.1532

2004

Link zum Volltext

Verfügbarkeit prüfen

Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers

The American journal of gastroenterology, 2012-03, Vol.107 (3), p.379-386

2012

Link zum Volltext

Verfügbarkeit prüfen

Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study

Journal of rheumatology, 2006-04, Vol.33 (4), p.659

2006

Link zum Volltext

Verfügbarkeit prüfen

Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results

Journal of rheumatology, 2003-04, Vol.30 (4), p.691

2003

Link zum Volltext

Verfügbarkeit prüfen

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry

Journal of rheumatology, 2011-07, Vol.38 (7), p.1273

2011

Link zum Volltext

Verfügbarkeit prüfen

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

The New England journal of medicine, 2000-11, Vol.343 (22), p.1586-1593

2000

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis

Arthritis care & research (2010), 2011-03, Vol.63 (3), p.373-382

2011

Link zum Volltext

Verfügbarkeit prüfen

Response to: ‘Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?’ by Fleishman and Yazici

Annals of the rheumatic diseases, 2014-09, Vol.73 (9), p.e55-e55

2014

Link zum Volltext

Verfügbarkeit prüfen

Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial

Journal of rheumatology, 2012-07, Vol.39 (7), p.1326

2012

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

The New England journal of medicine, 1997-07, Vol.337 (3), p.141-147

1997

Link zum Volltext

Verfügbarkeit prüfen

Preventing the progression from undifferentiated arthritis to rheumatoid arthritis: the clinical and economic implications

The American journal of managed care, 2010-11, Vol.16 (9 Suppl), p.S243

Schiff, Michael H

2010

Link zum Volltext

Verfügbarkeit prüfen

Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial

Journal of rheumatology, 2011-06, Vol.38 (6), p.990

2011

Link zum Volltext

Verfügbarkeit prüfen

Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries

Journal of rheumatology, 2011-01, Vol.38 (1), p.21

2011

Link zum Volltext

Verfügbarkeit prüfen

Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry

Current medical research and opinion, 2006-01, Vol.22 (1), p.185-198

2006

Link zum Volltext

Verfügbarkeit prüfen

Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis

Seminars in arthritis and rheumatism, 2000-12, Vol.30 (3), p.196-208

2000

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 185

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(150)

Publikationsform

Sprache

Englisch
(184)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Science & Technology
(131)
Life Sciences & Biomedicine
(125)
Humans
(120)
Female
(82)
Male
(78)
Middle Aged
(68)
Adult
(57)
Biological And Medical Sciences
(54)
Medical Sciences
(53)
Aged
(52)
Treatment Outcome
(46)
Arthritis, Rheumatoid - Drug Therapy
(38)
Rheumatology
(36)
Pharmacology. Drug Treatments
(30)
Antirheumatic Agents - Therapeutic Use
(26)
Double-Blind Method
(26)
Oncology
(25)
Rheumatoid Arthritis
(24)
General & Internal Medicine
(21)
Diseases Of The Osteoarticular System
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Integrated safety in tocilizumab clinical trials

Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)

Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration

Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience

Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis

Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase

Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study

Future Refinement of Methotrexate Treatment in Rheumatoid Arthritis: Comment on the Article by Yazdany et al

Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability

Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers

Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study

Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis

Response to: ‘Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?’ by Fleishman and Yazici

Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

Preventing the progression from undifferentiated arthritis to rheumatoid arthritis: the clinical and economic implications

Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial

Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries

Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry

Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis

Suchergebnisse filtern